Simulations Plus (NASDAQ:SLP) Posts Earnings Results, Beats Expectations By $0.02 EPS

Simulations Plus (NASDAQ:SLP) posted its quarterly earnings results on Wednesday. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02, Briefing.com reports. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The business had revenue of $18.70 million for the quarter, compared to analyst estimates of $19.73 million. During the same quarter last year, the business posted $0.18 EPS. The firm’s revenue for the quarter was up 19.9% on a year-over-year basis. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Down 0.9 %

Simulations Plus stock traded down $0.28 during trading hours on Friday, hitting $30.68. The stock had a trading volume of 276,597 shares, compared to its average volume of 130,076. The business’s 50 day simple moving average is $33.20 and its 200-day simple moving average is $40.76. Simulations Plus has a one year low of $29.37 and a one year high of $51.22. The stock has a market cap of $613.91 million, a price-to-earnings ratio of 64.50 and a beta of 0.69.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SLP. JMP Securities started coverage on Simulations Plus in a research note on Tuesday, July 16th. They issued a “market perform” rating on the stock. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research report on Thursday. KeyCorp began coverage on Simulations Plus in a research note on Monday, July 29th. They set an “overweight” rating and a $47.00 target price for the company. BTIG Research reduced their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Craig Hallum reiterated a “buy” rating and set a $56.00 price objective on shares of Simulations Plus in a research report on Wednesday, July 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Insider Transactions at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the transaction, the director now owns 3,501,592 shares in the company, valued at $123,186,006.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders have sold 60,750 shares of company stock worth $2,145,055. Insiders own 20.90% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.